Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Comparative, Multi-centric, Adaptive Design Clinical Study to Evaluate Efficacy, Safety, and Tolerability of 101-PGC-005 ('005) for the Treatment of Moderate Corona Virus Disease (COVID-19) Patients

NCT05656521 is registered in ClinicalTrials.gov with 101 Therapeutics as lead sponsor.

NCT NCT05656521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05656521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Comparative, Multi-centric, Adaptive Design Clinical Study to Evaluate Efficacy, Safety, and Tolerability of 101-PGC-005 ('005) for the Treatment of Moderate Corona Virus Disease (COVID-19) Patients
Lead sponsor
101 Therapeutics
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2023
Completion date
June 30, 2023
Enrollment
62 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19